Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.40 |
| ▸ | CTSL | P07711 | 6/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.35 |
| ▸ | HCK | P08631 | 1/20 | 0.34 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | CAPNS1 | P04632 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703752 | 0.89 | CTSK (0.47) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6703709 | 0.88 | CDK2 (0.39) | CTSKCTSLCTSSCTSBHCK | |
| SCHEMBL6705009 | 0.88 | CNR1 (0.37) | CTSKCTSLCTSSEPHA2 | |
| SCHEMBL6704787 | 0.87 | DRD2 (0.37) | CTSKCTSLCTSS | |
| SCHEMBL6698609 | 0.87 | HPGDS (0.37) | CTSKCTSLCTSSCTSBEPHA2 | |
| SCHEMBL6702842 | 0.86 | CTSL (0.39) | CTSKCTSLCTSSHCKNR2C2 | |
| SCHEMBL6752296 | 0.84 | CTSK (0.43) | CTSKCTSLCTSSCTSBHSPA5 | |
| SCHEMBL6294857 | 0.78 | CTSL (0.47) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6699225 | 0.78 | CTSK (0.53) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6702085 | 0.77 | HPGDS (0.45) | CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | CTSK 46/4885CTSL 15/4885CTSS 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.